Wedbush analyst David Nierengarten was out with some neutral comments on NPS Pharmaceuticals (NASDAQ:NPSP), following the news that the company’s Natpara has been approved by the FDA to …
Oppenheimer healthcare analyst Rohit Vanjani weighed in today with his thoughts on NPS Pharma (NASDAQ:NPSP), after the company and Shire (NASDAQ:SHPG) announced a definitive merger agreement whereby …
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of NPS Pharma (NASDAQ:NPSP) with a $42 price target, following concerns …